Juan Ruiz-Bañobre, M.D., Ph.D. , Principal Investigator of the Computational Oncology Group

Juan Ruiz-Bañobre is a physician (medical oncologist)-scientist in the Medical Oncology Department of the University Clinical Hospital of Santiago de Compostela and principal investigator of the Computational Oncology Group within the Oncomet structure in the Health Research Institute of Santiago de Compostela. As principal investigator, his role is to bridge the gap between practicing clinicians and biomedical scientists to bring discoveries from bench to bedside (and back again) in the field of oncology.
His main research interests include the development of molecular predictive biomarkers for various antineoplastic agents, the understanding of cancer evolution from multi-omics and immunological perspectives, as well as the development and translation of novel liquid biopsies approaches to help in cancer patient management. From a clinical and translational viewpoint, he is primarily focused on gastrointestinal cancers, genitourinary and gynecologic malignancies, and hereditary cancer predisposition syndromes.

Group members:

• Yoel Z. Betancor-Rivero. Biologist. Bioinformatician. PhD student.
• Natalia Fernández-Díaz. Physician. Resident of Medical Oncology. PhD student.
• Abraham Antón-Cameselle. Biologist. PhD student.
• Helena Lombardía-Rodríguez. Biologist. PhD student.

Alumni:

• Miriam Ferreiro-Pantín. Biologist. Bioinformatician. PhD student.
• Andrea Santisteban-Veiga. Biotechnologist. MSc student.
  
  

Selected publications:

• Casas-Arozamena, C., Vilar, A., Cueva, J., …, Ruiz-Bañobre J, … Muinelo-Romay L. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application. J Exp Clin Cancer Res. 2024. doi.org/10.1186/s13046-024-03158-w.

• Betancor YZ, Ferreiro-Pantin M &, Anido-Herranz U &, ..., Tubio JMC, López-López R >, Ruiz-Bañobre J >#. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma. Front. Immunol. 2024. doi.org/10.3389/fimmu.2024.1374728. &Equal contribution. >Co-senior authors. #Corresponding author.

• Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, ..., Ruiz-Bañobre J, Dhillon T, Gerlinger M. Genetic and immune landscape evolution in MMR deficient colorectal cancer. J. Pathol. 2023. doi:10.1002/path.6228.

• Arias-Diaz AE, Ferreiro-Pantín M, ..., Ruiz-Bañobre J, ..., Miguel Abal. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas. Int J Mol Sci. 2023. doi:10.3390/ijms241713208.

• Ferreiro-Pantín M, Anido-Herranz U &, Betancor YZ &, Cebey-López V, León-Mateos L, García-González J, García-Acuña SM, Fernández-Díaz N, Tubio JMC, López-López R >, Ruiz-Bañobre J >#. Clinical, molecular, and immune correlates of Immunotherapy Response Score in advanced urothelial carcinoma patients under atezolizumab monotherapy: Analysis of the phase 2 IMvigor210 trial. ESMO Open. 2023. doi:10.1016/j.esmoop.2023.101611. &Equal contribution. >Co-senior authors. #Corresponding author.

• Ruiz-Bañobre J, Goel A. Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer. Is It Ready for Prime Time? JAMA Oncology. 2023. doi:10.1001/jamaoncol.2023.0329.

• Dominguez-Valentin M, Haupt S, Seppälä T, ..., Ruiz-Bañobre J, ..., Moller P. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: A report from the Prospective Lynch Syndrome Database. eClinicalMedicine. 2023. doi.org/10.1016/j.eclinm.2023.101909.

• Santamarina-García M, Brea-Iglesias J, Bramsen JB, Fuentes-Losada M, Caneiro-Gómez FJ, Vázquez-Bueno JA, Lázare-Iglesias H, Fernández-Díaz N, Sánchez-Rivadulla L, Betancor YZ, Ferreiro-Pantín M, Conesa-Zamora P, Antúnez-López JR, Kawazu M, Esteller M, Andersen CL, Tubio JMC, López-López R #, Ruiz-Bañobre J #>. MSIMEP: predicting microsatellite instability from microarray DNA methylation tumor profiles. iScience. 2023;26(3). doi:10.1016/j.isci.2023.106127. #Co-corresponding author. >Lead contact.

• Casas-Arozamena C, Moiola CP, Vilar A, Bouso M, Cueva J, …, Ruiz-Bañobre J, López-López R, Moreno-Bueno G, Gil-Moreno A, Colás E, Abal M, Muinelo-Romay L. Non-Invasive Detection of Microsatellite Instability in patients with Endometrial Cancer. Int. J. Cancer. 2023. doi:10.1002/ijc.34435.

• Ruiz-Bañobre, J #, Rodriguez-Casanova A #, Costa-Fraga N. et al. Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA. Clin Epigenet. 2022;14:86. #Co-first author.

• Pérez-Martelo M, González-García A, ..., López-López R #, Ruiz-Bañobre J #. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy. Sci Rep. 2022;12:6893. #Co-corresponding author.

• Seervai RNH, Heberton M, ..., Ruiz-Bañobre J, ..., Curry JL. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. J. Cutan. Pathol. 2022;49(5):472-481.

• Álvarez EG, Demeulemeester J, Otero P, Jolly C, García-Souto D, ..., Ruiz-Bañobre J, ..., Tubio JMC. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun. 2021;12:6910.

• Ruiz-Bañobre J, Goel A. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in Cancer Research. Academic Press, Elsevier. 2021;151:231-304

• Ruiz-Bañobre J #, Molina-Díaz A, Fernández-Calvo O, et al. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.ESMO Open.2021;6(2):100090. #Corresponding author.

• Ruiz-Bañobre J, Roy R, Alustiza Fernández M, et al. Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation. Carcinogenesis.2020;41(11):1498-1506.

• Arias Ron D, Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Ruiz-Bañobre J, et al. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group. J Geriatr Oncol. 2021;12(3):410-415.

• García-González J #, Ruiz-Bañobre J #, Afonso-Afonso FJ, et al. PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. J Clin Med.2020;9(7). #Co-first and co-corresponding author.

• Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology. 2019;156(4):890-903.

• Ruiz-Bañobre J, Kandimalla R, Goel A. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. JCO Precis Oncol. 2019;(3):1-17.

• Ruiz-Bañobre J #, Areses-Manrique MC, Mosquera-Martínez J, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2019. #Co-corresponding author.

• Reimondez-Troitiño S, González-Aramundiz JV, Ruiz-Bañobre J, et al. Versatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells. Eur J Pharm Biopharm. 2019;142:449-459.

• Vázquez-Ríos AJ, Alonso-Nocelo M, López-Bouzo B, Ruiz-Bañobre J, de la Fuente-Freire M. 2018. Chapter 8: Nanotheranostics and Their Potential in the Management of Metastatic Cancer Handbook of Nanomaterials for Cancer Theranostics. Elsevier. ISBN 9780128133392.

• López-López R, Ruiz-Bañobre J, Muinelo-Romay L. 2018. Capítulo 3: Biopsia tisular versus biopsia líquida 50 Preguntas Clave en Oncología de Precisión. Permanyer. ISBN 9788417221416.

• Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz-Bañobre J, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325-1332.

• Ruiz-Bañobre J #, Garcia-Gonzalez J. Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective. J Eur Acad Dermatol Venereol. 2017;31(9):e407-e408. #Corresponding author.

• Ruiz-Bañobre J #, Abdulkader I, Anido U, Leon L, Lopez-Lopez R, Garcia-Gonzalez J. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. APMIS. 2017;125(3):259-263. #Corresponding author.

• Ruiz-Bañobre J #, Pérez-Pampín E, García-González J, et al. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer. 2017;0(0). #Corresponding author.

• Ruiz-Bañobre J #, Anido U, García-González J. Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al’s Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcom. Eur Urol. July 2016. #Corresponding author.

• Ruiz-Bañobre J #, Anido U, Abdulkader I, Antunez-Lopez J, Lopez-Lopez R, Garcia-Gonzalez J. Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. Front Oncol. 2016;6:250. #Corresponding author.

• Sánchez-Ares M, Cameselle-Teijeiro JM, ..., Ruiz-Bañobre J, ..., Abdulkader I. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). Oncol Lett. 2016;12:1403–7.